BACKGROUND:Children have a lower response rate to antimonial drugs and higher elimination rate of antimony (Sb) than adults. Oral miltefosine has not been evaluated for pediatric cutaneous leishmaniasis. METHODS: A randomized, noninferiority clinical trial with masked evaluation was conducted at 3 locations in Colombia where Leishmania panamensis and Leishmania guyanensis predominated. One hundred sixteen children aged 2-12 years with parasitologically confirmed cutaneous leishmaniasis were randomized to directly observed treatment with meglumine antimoniate (20 mg Sb/kg/d for 20 days; intramuscular) (n = 58) or miltefosine (1.8-2.5 mg/kg/d for 28 days; by mouth) (n = 58). Primary outcome was treatment failure at or before week 26 after initiation of treatment. Miltefosine was noninferior if the proportion of treatment failures was ≤15% higher than achieved with meglumine antimoniate (1-sided test, α = .05). RESULTS:Ninety-five percent of children (111/116) completed follow-up evaluation. By intention-to-treat analysis, failure rate was 17.2% (98% confidence interval [CI], 5.7%-28.7%) for miltefosine and 31% (98% CI, 16.9%-45.2%) for meglumine antimoniate. The difference between treatment groups was 13.8%, (98% CI, -4.5% to 32%) (P = .04). Adverse events were mild for both treatments. CONCLUSIONS:Miltefosine is noninferior to meglumine antimoniate for treatment of pediatric cutaneous leishmaniasis caused by Leishmania (Viannia) species. Advantages of oral administration and low toxicity favor use of miltefosine in children. CLINICAL TRIAL REGISTRATION: NCT00487253.
RCT Entities:
BACKGROUND:Children have a lower response rate to antimonial drugs and higher elimination rate of antimony (Sb) than adults. Oral miltefosine has not been evaluated for pediatric cutaneous leishmaniasis. METHODS: A randomized, noninferiority clinical trial with masked evaluation was conducted at 3 locations in Colombia where Leishmania panamensis and Leishmania guyanensis predominated. One hundred sixteen children aged 2-12 years with parasitologically confirmed cutaneous leishmaniasis were randomized to directly observed treatment with meglumine antimoniate (20 mg Sb/kg/d for 20 days; intramuscular) (n = 58) or miltefosine (1.8-2.5 mg/kg/d for 28 days; by mouth) (n = 58). Primary outcome was treatment failure at or before week 26 after initiation of treatment. Miltefosine was noninferior if the proportion of treatment failures was ≤15% higher than achieved with meglumine antimoniate (1-sided test, α = .05). RESULTS: Ninety-five percent of children (111/116) completed follow-up evaluation. By intention-to-treat analysis, failure rate was 17.2% (98% confidence interval [CI], 5.7%-28.7%) for miltefosine and 31% (98% CI, 16.9%-45.2%) for meglumine antimoniate. The difference between treatment groups was 13.8%, (98% CI, -4.5% to 32%) (P = .04). Adverse events were mild for both treatments. CONCLUSIONS:Miltefosine is noninferior to meglumine antimoniate for treatment of pediatric cutaneous leishmaniasis caused by Leishmania (Viannia) species. Advantages of oral administration and low toxicity favor use of miltefosine in children. CLINICAL TRIAL REGISTRATION: NCT00487253.
Authors: A Corredor; R D Kreutzer; R B Tesh; J Boshell; M T Palau; E Caceres; S Duque; D Pelaez; G Rodriguez; S Nichols Journal: Am J Trop Med Hyg Date: 1990-03 Impact factor: 2.345
Authors: Juan Carlos Vega; Boris Fernando Sanchez; Luz Mery Montero; Rafael Montaña; Mercedes Del Pilar Mahecha; Bladimir Dueñes; Angela Rocío Baron; Richard Reithinger Journal: Trop Med Int Health Date: 2007-12 Impact factor: 2.622
Authors: M Mohebali; A Fotouhi; B Hooshmand; Z Zarei; B Akhoundi; A Rahnema; A R Razaghian; M J Kabir; A Nadim Journal: Acta Trop Date: 2007-05-18 Impact factor: 3.112
Authors: Andrés Felipe Uribe-Restrepo; Miguel Dario Prieto; Alexandra Cossio; Mayur M Desai; María Del Mar Castro Journal: Am J Trop Med Hyg Date: 2019-02 Impact factor: 2.345
Authors: Luuk C T Dohmen; Adriana Navas; Deninson Alejandro Vargas; David J Gregory; Anke Kip; Thomas P C Dorlo; Maria Adelaida Gomez Journal: J Biol Chem Date: 2016-02-22 Impact factor: 5.157
Authors: Caroline R Espada; Fatima Ribeiro-Dias; Miriam L Dorta; Ledice Inácia de Araújo Pereira; Edgar M de Carvalho; Paulo R Machado; Albert Schriefer; Jenicer K U Yokoyama-Yasunaka; Adriano C Coelho; Silvia R B Uliana Journal: Am J Trop Med Hyg Date: 2017-04-06 Impact factor: 2.345